vs
Apellis Pharmaceuticals, Inc.（APLS）与Innovex International, Inc.（INVX）财务数据对比。点击上方公司名可切换其他公司
Innovex International, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.4倍（$273.6M vs $199.9M），Innovex International, Inc.净利率更高（5.1% vs -29.5%，领先34.6%），Innovex International, Inc.同比增速更快（9.1% vs -5.9%），过去两年Innovex International, Inc.的营收复合增速更高（46.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
APLS vs INVX — 直观对比
营收规模更大
INVX
是对方的1.4倍
$199.9M
营收增速更快
INVX
高出15.1%
-5.9%
净利率更高
INVX
高出34.6%
-29.5%
两年增速更快
INVX
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $273.6M |
| 净利润 | $-59.0M | $14.0M |
| 毛利率 | — | 28.9% |
| 营业利润率 | -25.6% | 9.4% |
| 净利率 | -29.5% | 5.1% |
| 营收同比 | -5.9% | 9.1% |
| 净利润同比 | -62.2% | -56.1% |
| 每股收益（稀释后） | $-0.40 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSINVX
| Q4 25 | $199.9M | $273.6M | ||
| Q3 25 | $458.6M | $240.0M | ||
| Q2 25 | $178.5M | $224.2M | ||
| Q1 25 | $166.8M | $240.4M | ||
| Q4 24 | $212.5M | $250.7M | ||
| Q3 24 | $196.8M | $151.8M | ||
| Q2 24 | $199.7M | $130.3M | ||
| Q1 24 | $172.3M | $128.0M |
净利润APLSINVX
| Q4 25 | $-59.0M | $14.0M | ||
| Q3 25 | $215.7M | $39.2M | ||
| Q2 25 | $-42.2M | $15.3M | ||
| Q1 25 | $-92.2M | $14.8M | ||
| Q4 24 | $-36.4M | $31.8M | ||
| Q3 24 | $-57.4M | $82.6M | ||
| Q2 24 | $-37.7M | $9.5M | ||
| Q1 24 | $-66.4M | $16.4M |
毛利率APLSINVX
| Q4 25 | — | 28.9% | ||
| Q3 25 | — | 31.6% | ||
| Q2 25 | — | 32.0% | ||
| Q1 25 | — | 31.8% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 34.7% | ||
| Q2 24 | — | 35.3% | ||
| Q1 24 | — | 38.4% |
营业利润率APLSINVX
| Q4 25 | -25.6% | 9.4% | ||
| Q3 25 | 48.7% | 26.0% | ||
| Q2 25 | -18.6% | 10.1% | ||
| Q1 25 | -50.0% | 9.1% | ||
| Q4 24 | -12.3% | 10.7% | ||
| Q3 24 | -24.0% | -8.7% | ||
| Q2 24 | -14.7% | 10.0% | ||
| Q1 24 | -36.0% | 17.4% |
净利率APLSINVX
| Q4 25 | -29.5% | 5.1% | ||
| Q3 25 | 47.0% | 16.3% | ||
| Q2 25 | -23.6% | 6.8% | ||
| Q1 25 | -55.3% | 6.1% | ||
| Q4 24 | -17.1% | 12.7% | ||
| Q3 24 | -29.2% | 54.4% | ||
| Q2 24 | -18.9% | 7.3% | ||
| Q1 24 | -38.5% | 12.8% |
每股收益（稀释后）APLSINVX
| Q4 25 | $-0.40 | $0.20 | ||
| Q3 25 | $1.67 | $0.57 | ||
| Q2 25 | $-0.33 | $0.22 | ||
| Q1 25 | $-0.74 | $0.21 | ||
| Q4 24 | $-0.30 | $-0.03 | ||
| Q3 24 | $-0.46 | $1.99 | ||
| Q2 24 | $-0.30 | $0.30 | ||
| Q1 24 | $-0.54 | $0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $18.9M |
| 股东权益账面价值 | $370.1M | $1.1B |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | 0.02× |
8季度趋势，按日历期对齐
现金及短期投资APLSINVX
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | $185.6M | ||
| Q1 24 | $325.9M | $202.2M |
总债务APLSINVX
| Q4 25 | — | $18.9M | ||
| Q3 25 | — | $20.1M | ||
| Q2 25 | — | $34.8M | ||
| Q1 25 | — | $19.7M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $12.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSINVX
| Q4 25 | $370.1M | $1.1B | ||
| Q3 25 | $401.2M | $1.0B | ||
| Q2 25 | $156.3M | $995.6M | ||
| Q1 25 | $164.2M | $978.4M | ||
| Q4 24 | $228.5M | $958.2M | ||
| Q3 24 | $237.1M | $904.4M | ||
| Q2 24 | $264.3M | $352.5M | ||
| Q1 24 | $266.7M | $344.3M |
总资产APLSINVX
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | $1.2B | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $1.1B | ||
| Q2 24 | $904.5M | $1.0B | ||
| Q1 24 | $831.9M | $1.0B |
负债/权益比APLSINVX
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $52.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 3.74× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSINVX
| Q4 25 | $-14.2M | $52.2M | ||
| Q3 25 | $108.5M | $48.4M | ||
| Q2 25 | $4.4M | $59.2M | ||
| Q1 25 | $-53.4M | $31.1M | ||
| Q4 24 | $19.4M | $36.3M | ||
| Q3 24 | $34.1M | $21.7M | ||
| Q2 24 | $-8.3M | $22.8M | ||
| Q1 24 | $-133.0M | $12.6M |
自由现金流APLSINVX
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | $16.6M | ||
| Q1 24 | $-133.3M | $7.8M |
自由现金流率APLSINVX
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | 12.7% | ||
| Q1 24 | -77.3% | 6.1% |
资本支出强度APLSINVX
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | 4.7% | ||
| Q1 24 | 0.2% | 3.7% |
现金转化率APLSINVX
| Q4 25 | — | 3.74× | ||
| Q3 25 | 0.50× | 1.23× | ||
| Q2 25 | — | 3.86× | ||
| Q1 25 | — | 2.11× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | 2.39× | ||
| Q1 24 | — | 0.77× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
INVX
| Products | $202.7M | 74% |
| Leasing | $42.3M | 15% |
| Services | $28.6M | 10% |
